Tags : an Immuno-Oncology

Amgen Signs an Immuno-Oncology Agreement with Molecular Partners’ for its

Shots: Molecular to receive $50M upfront, $497M milestone and royalties on sales and also has certain rights to commercialize DARPin based products with MP0310. Amgen to get exclusive worldwide development and commercialization rights for Molecular’s MP0310 The companies will jointly evaluate MP0310 with Amgen’s oncology product and BiTE (bispecific T cell engager) molecules, with defined cost sharing for first three indications Molecular’s […]Read More